"Having full ownership of this important program allows Recursion to accelerate the development of the first potential oral disease-modifying treatment to HPP patients, who currently face ...

Under the agreement, Rallybio will also receive low single-digit royalties on future net sales and may be eligible for additional payments if Recursion sells the program.

The program originated from a joint venture between the two companies that combined Rallybio’s expertise in HPP research with Recursion’s AI platform. Under the agreement, Rallybio will also receive ...